Incyte Corporation (INCY) Stock Price Today
24H
1W
1M
3M
YTD
1Y
5Y
Overview
Financial
Technicals
Analysis
Corporate Action
About
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Technical Indicators
|
|
|
Overall Summary
Bearish (1)Neutral (11)Bullish (15)
Performance
INCY ROI
+44.71%% from 52W High-8.54%
52W Low: $55.17
10 Apr 2025
52W High: $108.26
12 Nov 2025
News
US Stocks risk is managed by PT PG Berjangka which has a license from the Badan Pengawas Perdagangan Berjangka Komoditi (BAPPEBTI), and your investment is guaranteed by the Jakarta Futures Exchange (JFX) and the Indonesian Clearing House (KBI). Read our product’s Terms and Conditions. View Terms and Conditions
Let’s trade or invest in this asset by signing up or logging in!
You can also download our app!
